MetaCap

Septerna (SEPN) vs Stoke Therapeutics (STOK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Septerna (SEPN) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 51.1% versus a loss of 8.6%. Septerna is the larger company by market cap ($1.84 billion vs $1.75 billion), about 1.0 times the size. Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -106.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SEPN+51.06%STOK-8.62%
+111%+41%-30%
Nov 21, 20251 yearNov 20, 2026
SEPN+80.42%STOK+125.10%
+227%+69%-89%
Oct 21, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SEPN versus STOK key metrics
MetricSEPNSTOK
Share price$38.61$26.81
Market cap$1.84B$1.75B
1-day change-1.51%-0.45%
YTD return+38.49%-15.53%
1-year return+51.06%-8.62%
5-year return—+6.77%
EPS (TTM)$-1.30$-3.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$45.95M$184.42M
Revenue growth (YoY)+4174.51%+404.50%
Net income (latest FY)$-48.88M$-6.88M
Operating margin-148.63%-11.16%
Net margin-106.37%-3.73%
52-week high$53.34$40.22
52-week low$22.78$22.05
Distance from 52-week high-27.62%-33.34%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+53.38%+73.00%
Average volume383.96K1.02M
Shares outstanding47.55M65.41M
Employees134170
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SEPN has outperformed STOK by 59.7 percentage points over the past year.
  • Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -106.4 cents for Septerna.
  • Septerna grew revenue faster in its latest fiscal year (+4174.51% vs +404.50%).

About Septerna

SEPN stock →

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees

About Stoke Therapeutics

STOK stock →

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees

SEPN vs STOK FAQ

Which is bigger, Septerna or Stoke Therapeutics?

Septerna (SEPN) is larger, with a market capitalization of $1.84B compared with $1.75B for Stoke Therapeutics (STOK).

Which stock has performed better over the past year, SEPN or STOK?

SEPN returned +51.06% over the past 12 months, compared with -8.62% for STOK (price return, excluding dividends). Past performance does not predict future results.

Are Septerna and Stoke Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons